Systemic oncological treatments in patients with advanced pancreatic cancer: a scoping review and evidence map
-
Published:2023-01-09
Issue:2
Volume:31
Page:
-
ISSN:0941-4355
-
Container-title:Supportive Care in Cancer
-
language:en
-
Short-container-title:Support Care Cancer
Author:
Salazar JosefinaORCID, Bracchiglione JavierORCID, Acosta-Dighero Roberto, Meza NicolasORCID, Meade Adriana-G.ORCID, Quintana María Jesús, Requeijo CarolinaORCID, Rodríguez-Grijalva Gerardo, Santero MarilinaORCID, Selva AnnaORCID, Solà Ivan, Bonfill Xavier, Salas Karla, Antequera Alba, Auladell-Rispau Ariadna, Urrútia Gerard, Meinardi Pamela, Irassar Juan, Simancas Daniel, Dorantes Rosario, Merchán Angela, Cantero Yahveth, Hernandez Edgar, Sugrañes Miguel,
Abstract
Abstract
Purpose
To identify, describe, and organise currently available evidence regarding systemic oncological treatments (SOTs) (chemotherapy, targeted/biological therapies, and immunotherapy) compared to best supportive care (BSC) for patients with advanced pancreatic cancer (PC).
Methods
We conducted a scoping review and evidence mapping, adhering to PRISMA-ScR checklist. We searched MEDLINE, EMBASE, Cochrane Library, Epistemonikos, PROSPERO, and clinicaltrials.gov for eligible studies. We included systematic reviews (SRs), randomised controlled trials (RCTs), quasi-experimental, and observational studies evaluating SOTs compared to BSC or no treatment in patients with advanced PC. Two independent reviewers performed the screening process and data extraction. We developed evidence maps as an interactive visualization display, including the assessed interventions and outcomes.
Results
Of the 50,601 records obtained from our search, we included 43 studies: 2 SRs, 16 RCTs, 4 quasi-experimental studies, 20 observational studies, and 1 protocol for a quasi-experimental study. Forty-two studies reported survival-related outcomes and most favoured SOTs, while five reported toxicity and most favoured BSC. Other patient-centred outcomes, such as quality of life, were scarcely reported.
Conclusions
This study highlights the current evidence gaps in studies assessing treatments for patients with advanced PC, mainly the lack of reports of non-survival-related outcomes, pointing out research areas that need further attention to make better recommendations for these patients.
Funder
Instituto de Salud Carlos III European Regional Development Fund Universitat Autònoma de Barcelona
Publisher
Springer Science and Business Media LLC
Reference68 articles.
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71(3):209–249. https://doi.org/10.3322/caac.21660 2. National Cancer Institute. Surveillance Research Program, SEER*Explorer: An interactive website for SEER cancer statistics, US National Institutes of Health. Retreived April 6, 2022 from https://seer.cancer.gov/explorer/ 3. Hui D, Nooruddin Z, Didwaniya N, Dev R, De La Cruz M, Kim SH, Kwon JH, Hutchins R, Liem C, Bruera E (2014) Concepts and definitions for “actively dying,” “end of life,” “terminally ill,” “terminal care,” and “transition of care”: a systematic review. J Pain Symptom Manage 47(1):77–89. https://doi.org/10.1016/j.jpainsymman.2013.02.021 4. PDQ Supportive and Palliative Care Editorial Board. (2022). Planning the Transition to End-of-Life Care in Advanced Cancer (PDQ®): Health Professional Version. In PDQ Cancer Information Summaries. National Cancer Institute (US). 5. Mossman B, Perry LM, Walsh LE, Gerhart J, Malhotra S, Horswell R, Chu S, Raines AM, Lefante J, Blais CM, Miele L, Melancon B, Alonzi S, Voss H, Freestone L, Dunn A, Hoerger M (2021) Anxiety, depression, and end-of-life care utilization in adults with metastatic cancer. Psychooncology 30(11):1876–1883. https://doi.org/10.1002/pon.5754
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|